Publications utiles
Classifications
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011 May 12 ;117(19) :5019-32.
Campo, E. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140, 1229–1253 (2022).
Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720–1748 (2022).
Stadification
Teillet F, Weisgerber C, Desprez-Curely JP, Bousquet R, Boiron M, Bernard J. L´extension du processus hodgkinien. Étude clinique. Bull Cancer 1971 ; 58 : 45-56.
Rosenberg SA: Validity of the Ann Arbor staging classification for the non-hodgkin’s lymphomas. Cancer Treat Rep 61 :1023-1027, 1977
Lister TA, Crowther D, Sutcliffe SB, et al. Report of the committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds Meeting. J Clin Oncol 7 :1630-1636, 1989
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 ; 25 :579-586.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68.
Facteurs de risque
Lymphome de Hodgkin
Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, Van der Schueren E et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin´s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989 ; 73 : 47-56
Somers R, Henry-Amar M, Meerwaldt JK, Carde P, eds. Treatment strategy in Hodgkin’s disease. Colloque INSERM N° 196. London : INSERM/John Libbey Eurotext, 1990 :169-422.
Sieber M, Engert A, Diehl V. Treatment of Hodgkin’s disease: results and current concepts of the German Hodgkin’s Lymphoma Study Group. Ann Oncol 2000 ;11 Suppl 1:81-5.
Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin’s lymphoma. Eur J Haematol 2005 ;66(suppl):135-40.
Lymphome folliculaire
Gallagher CJ, Gregory WM, Jones EA, et al. Follicular lymphoma : prognostic factors for response and survival. J Clin Oncol 1986 ;4 :1470-80.
Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009 Sep 20 ;27(27):4555-62.
Lymphomes T périphériques
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004 Apr 1 ;103(7) :2474-9.
| Index pronostiques
Lymphome diffus à grandes cellules B Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-hodgkin’s lymphoma. The International Non-Hodgkin Lymphoma Prognostic Factor Project. N Engl J Med 1993 ;329 :987-94. Shen LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007 March 1 ;109 :1857-1861. Maurer MJ, Ghesquières H, Jais JP, et al. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol 2014 Apr 1;32(10):1066-73. |
| Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in patients with Diffuse Large B-Cell Lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(24):3150-3156.
Lymphome à cellules du manteau Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic indes in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol 2014 May 1;32(13):1338-46. Lymphome folliculaire Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004 ;104 :1258-65. |
Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004 Apr 1;103(7):2474-9.
Lymphomes indolents non folliculaires
Montalban C, Abraira V, Arcaini L, et al. Splenic Marginal Zone Lymphoma Study Group. Risk stratification for splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012,159(2):164-171.
Montalban C, Abraira V, Arcaini L, et al. Splenic Marginal Zone Lymphoma Study Group. (SMZLSG). Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2014 Apr;55(4):929-31.
Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood 2017 Sep 21;130(12):1409-1417.
Lymphome de Hodgkin
Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin’s Disease: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998; 339:1506-14.
Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Annal Oncol 2013 Sep ;24(9) :2430-4.
Evaluation de la réponse
Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244-1253, 1999.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25:579-86.
Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059-3068.
TEP
Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009 Aug; 50(8): 1257-60.
Meignan M, Gallamini A , Itti E , Barrington S, Haioun C, Polliack A. Report on the third international workshop on Interim Positron Emission Tomography in lymphoma held in Menton, France, 26 – 27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. Leuk Lymphoma. 2012 Oct;53(10):1876-81.
Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014 Jan;55(1):31-7.
Barrington SF, Mikhaeel NG, Kostakoglu et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048-3058.
Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM: secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018; 19:1530-42.
Recommandations
Eichenauer DA, Engert A, André M et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Haematological malignancies Vol 29, Supp 4, IV19-IV29, Oct 2018.
Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 32, 298-308 (2021).
Hoang-Xuan K, Deckert M, Ferreri AJM,et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncol 2023 Jan 5 ;25(1):37-53.
Rossi C, Manson G, Marouf A, et al. Classic Hodgkin lymphoma : the LYSA Pragmatic Guidelines. Eur J Cancer, 2024 Oct 22 :213 :115073.
D’Amore F, Federico M, de Leval F, et al. Peripheral T- and natural killer-cell lymphomas : ESMO-EHA Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 36, 626–644 (2025).
Radiothérapie
Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006 ; 79 :270-77.
Specht L, Yahalom J, Illidge T, et al. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys, 2013 Jun 18. pii:S0360-3016(13)00534-8.